Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: Cohort study to derive and validate the QBleed scores

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Hippisley Cox, Julia ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID; HEMOGLOBIN; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BRAIN HEMORRHAGE; CLASSIFICATION ALGORITHM; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; FEMALE; GENDER; GENERAL PRACTICE; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; MIDDLE AGED; MORTALITY; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QBLEED SCORE; RISK ASSESSMENT; SCORING SYSTEM; SMOKING; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE COUNT; TOWNSEND DEPRIVATION SCORE; UPPER GASTROINTESTINAL BLEEDING; VALIDATION PROCESS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; EPIDEMIOLOGIC METHODS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84904877971     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4606     Document Type: Article

References (46)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-67.
2. National Institute for Health and Care Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. (Clinical guideline 92.) 2010. http://guidance.nice.org. uk/CG92.
3. National Clinical Guideline Centre. Atrial fibrillation: the management of atrial fibrillation. Clinical guideline, methods, evidence and recommendations. (Clinical guideline 180.) 2014. www.nice.org.uk/guidance/cg180/ resources/cg180-atrial-fibrillation-update-full-guideline3.
4. Hippisley-Cox J, Coupland C. Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study. BMJ 2011; 343:d4656.
5. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ 2013; 346:f2573.
6. Health & Social Care Information Centre. The Quality and Outcomes Framework. 2013. www.ic.nhs.uk/services/qof.
7. Lip GY. Atrial fibrillation in 2011: stroke prevention in AF. Nat Rev Cardiol 2012; 9:71-3.
8. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110:453-60.
9. Tata LJ, Fortun PJ, Hubbard RB, Smeeth L, Hawkey C.J., Smith CJ, et al. Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005; 22:175-81.
10. Gage BF, Yan Y, Milligan PE, Waterman A.D., Culverhouse R., Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713-9.
11. Go AS, Hylek EM, Borowsky LH, Phillips K.A., Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 1999; 131:927-34.
12. Donze J, Rodondi N, Waeber G, Monney P., Cornuz J, Aujesky D. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med 2012; 125:1095-102.
13. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138:1093-100.
14. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D., Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14:1385-413.
15. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GYH. Performance of the HEMORR2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. J Am Coll Cardiol 2012; 60:861-7.
16. Olesen JB, Pisters R, Roldans V, Marin F., Lane DA. The ATRIA risk scheme to predict warfarin-associated hemorrhage not ready for clinical use. J Am Coll Cardiol 2012; 59:194-5.
17. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J., May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007; 335:136.
18. Hippisley-Cox J, Vinogradova Y, Coupland C, Pringle M. Comparison of key practice characteristics between general practices in England and Wales and general practices in the QRESEARCH data. Report to the Health and Social Care Information Centre: University of Nottingham, 2005.
19. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J., Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 2008; 94:34-9.
20. Johnson ES, Bartman BA, Briesacher BA, Fleming N.S., Gerhard T., Kornegay CJ, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 2013; 22:1-6.
21. Hippisley-Cox J, Coupland C. Predicting risk of emergency admission to hospital using primary care data: derivation and validation of QAdmissions score. BMJ Open 2013; 3(8):e003482.
22. Hippisley-Cox J. Validity and completeness of the NHS number in primary and secondary care electronic data in England 1991-2013. QResearch 2013:14. www.qresearch.org.uk.
23. Button L, Roberts S, Evans P. Hospitalized incidence and case fatality for upper gastrointestinal bleeding from 1999 to 2007: a record linkage study. Aliment Pharmacol Ther 2011; 33:64-76.
24. Crooks C, West J, Card T. Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissions. Gut 2011; 61:514-20.
25. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J., Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336:1475-82.
26. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 2012; 344:e3427.
27. Schafer J, Graham J. Missing data: our view of the state of the art. Psychol Methods 2002; 7:147-77.
28. The Academic Medicine Group. Academic medicine: problems and solutions. BMJ 1989; 298:573-9.
29. Steyerberg EW, van Veen M. Imputation is beneficial for handling missing data in predictive models. J Epidemiol Community Health 2007; 60:979.
30. Moons KGM, Donders RART, Stijnen T, Harrell FJ. Using the outcome for imputation of missing predictor values was preferred. J Epidemiol Community Health 2006; 59:1092.
31. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28:964-74.
32. Royston P, Sauerbrei W. A new measure of prognostic separation in survival data. Stat Med 2004; 23:723-48.
33. Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods. BMC Med Res Methodol 2013; 13:33.
34. Rockall T, Lofan R, Devlin H, Northfield T. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. BMJ 1995; 311:222-6.
35. Nilsson OG, Lindgren A, Stahl N, Brandt L., Saveland H. Incidence of intracerebral and subarachnoid haemorrhage in southern Sweden. J Neurol Neurosurg Psychiatry 2000; 69:601-7.
36. Van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010; 9:167-76.
37. Food and Drug Administration. A protocol for assessment of dabigatran and selected safety outcomes 2013. http://mini-sentinel.org/assessments/medical- events/details.aspx?ID=219.
38. Hippisley-Cox J, Coupland C, Robson J, Sheikh A., Brindle P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. BMJ 2009; 338:b880.
39. Hippisley-Cox J, Coupland C. Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney(R) Scores. BMC Fam Pract 2010; 11:49.
40. Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009; 339:b4229.
41. Collins GS, Mallett S, Altman DG. Predicting risk of osteoporotic and hip fracture in the United Kingdom: prospective independent and external validation of QFractureScores. BMJ 2011; 342:d3651.
42. Collins GS, Altman DG. External validation of the QDScore for predicting the 10-year risk of developing type 2 diabetes. Diabet Med 2011; 28:599-607.
43. Majeed A. Sources, uses, strengths and limitations of data collected in primary care in England. Health Stat Q 2004:5-14.
44. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast P.G., Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360:1071-3.
45. Collins GS, Altman A. Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2. BMJ 2012; 344:e4181.
46. Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ 2010; 340:c2442.